Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1Liver Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrence × BIIB022 × Clear all
NCT00555724 2017-01-09

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

Biogen

Phase 1 Completed
40 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡